Jefferies: For Insilico Medicine (03696.HK), drug assets are more important than proprietary models; maintain "Buy" rating.

Zhito Finance APP has learned that Jefferies issued a research report stating that the management of Insilico Medicine (03696.HK) reiterated at the bank's Asia-Pacific Healthcare Conference that the company is shifting from platform validation to asset and recurring milestone conversion. The bank maintained its "Buy" rating and target price of HK$100 for the stock.